Publication:
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients

3

Issued Date

2021-02-01

Resource Type

Article

ISSN

19360541
19360533

DOI

10.1007/s12072-020-10113-2

Other identifier(s)

2-s2.0-85098964636

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Hepatology International. Vol.15, No.1 (2021), 71-81

Suggested Citation

Matt Liu, Tai Chung Tseng, Dae Won Jun, Ming Lun Yeh, Huy Trinh, Grace L.H. Wong, Chien Hung Chen, Cheng Yuan Peng, Sung Eun Kim, Hyunwoo Oh, Min Sun Kwak, Michael Cheung, Hidenori Toyoda, Yao Chun Hsu, Jae Yoon Jeong, Eileen L. Yoon, Teerapat Ungtrakul, Jian Zhang, Qing Xie, Sang Bong Ahn, Masaru Enomoto, Jae Jun Shim, Chris Cunningham, Soung Won Jeong, Yong Kyun Cho, Eiichi Ogawa, Rui Huang, Dong Hyun Lee, Hirokazu Takahashi, Pei Chien Tsai, Chung Feng Huang, Chia Yen Dai, Cheng Hao Tseng, Satoshi Yasuda, Ritsuzo Kozuka, Jiayi Li, Christopher Wong, Clifford C. Wong, Changqing Zhao, Joseph Hoang, Yuichiro Eguchi, Chao Wu, Yasuhito Tanaka, Ed Gane, Tawesak Tanwandee, Ramsey Cheung, Man Fung Yuen, Hyo Suk Lee, Ming Lung Yu, Jia Horng Kao, Hwai I. Yang, Mindie H. Nguyen Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatology International. Vol.15, No.1 (2021), 71-81. doi:10.1007/s12072-020-10113-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78486

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients

Author(s)

Matt Liu
 Tai Chung Tseng
 Dae Won Jun
 Ming Lun Yeh
 Huy Trinh
 Grace L.H. Wong
 Chien Hung Chen
 Cheng Yuan Peng
 Sung Eun Kim
 Hyunwoo Oh
 Min Sun Kwak
 Michael Cheung
 Hidenori Toyoda
 Yao Chun Hsu
 Jae Yoon Jeong
 Eileen L. Yoon
 Teerapat Ungtrakul
 Jian Zhang
 Qing Xie
 Sang Bong Ahn
 Masaru Enomoto
 Jae Jun Shim
 Chris Cunningham
 Soung Won Jeong
 Yong Kyun Cho
 Eiichi Ogawa
 Rui Huang
 Dong Hyun Lee
 Hirokazu Takahashi
 Pei Chien Tsai
 Chung Feng Huang
 Chia Yen Dai
 Cheng Hao Tseng
 Satoshi Yasuda
 Ritsuzo Kozuka
 Jiayi Li
 Christopher Wong
 Clifford C. Wong
 Changqing Zhao
 Joseph Hoang
 Yuichiro Eguchi
 Chao Wu
 Yasuhito Tanaka
 Ed Gane
 Tawesak Tanwandee
 Ramsey Cheung
 Man Fung Yuen
 Hyo Suk Lee
 Ming Lung Yu
 Jia Horng Kao
 Hwai I. Yang
 Mindie H. Nguyen

Other Contributor(s)

Osaka Metropolitan University
 Hanyang University Hospital
 Siriraj Hospital
 Massey University Wellington
 Good Gang-An Hospital
 Academia Sinica, Genomics Research Center
 E-Da Hospital
 Shanghai Jiao Tong University School of Medicine
 Inje University Paik Hospital
 Chang Gung University College of Medicine
 Kaohsiung Medical University Chung-Ho Memorial Hospital
 National Taiwan University Hospital
 Saga University Hospital
 China Medical University Hospital
 Eulji University, School of Medicine
 Palo Alto Medical Foundation
 Kyung Hee Medical Center
 Soonchunhyang University, College of Medicine
 Chulabhorn Royal Academy
 Kyushu University Hospital
 SKKU School of Medicine
 Stanford University Medical Center
 University of Washington
 Auckland City Hospital
 Shanghai University of Traditional Chinese Medicine
 The University of Hong Kong
 Hallym University, College of Medicine
 Medical School of Nanjing University
 Nagoya City University Graduate School of Medical Sciences
 Chinese University of Hong Kong
 Ogaki Municipal Hospital
 Seoul National University College of Medicine
 Wong Clinics
 National Medical Center
 Chinese Hospital
 San Jose Gastroenterology

Abstract

Background: Increasing hepatitis-related mortality has reignited interest to fulfill the World Health Organization’s goal of viral hepatitis elimination by 2030. However, economic barriers have enabled only 28% of countries to implement countermeasures. Given the high disease burden among Asians, we aimed to present age, sex, disease activity and treatment-specific annual progression rates among Asian chronic hepatitis B (CHB) patients to inform health economic modeling efforts and cost-effective public health interventions. Methods: We analyzed 18,056 CHB patients from 36 centers across the U.S. and seven countries/regions of Asia Pacific (9530 treated; 8526 untreated). We used Kaplan–Meier methods to estimate annual incidence of cirrhosis and hepatocellular carcinoma (HCC). Active disease was defined by meeting the APASL treatment guideline criteria. Results: Over a median follow-up of 8.55 years, there were 1178 incidences of cirrhosis and 1212 incidences of HCC (297 without cirrhosis, 915 with cirrhosis). Among the 8526 untreated patients (7977 inactive, 549 active), the annual cirrhosis and HCC incidence ranged from 0.26% to 1.30% and 0.04% to 3.80% in inactive patients, and 0.55 to 4.05% and 0.19 to 6.03% in active patients, respectively. Of the 9530 treated patients, the annual HCC rates ranged 0.03–1.57% among noncirrhotic males and 2.57–6.93% among cirrhotic males, with lower rates for females. Generally, transition rates increased with age, male sex, the presence of fibrosis/cirrhosis, and active disease and/or antiviral treatment. Conclusion: Using data from a large and diverse real-world cohort of Asian CHB patients, the study provided detailed annual transition rates to inform practice, research and public health planning.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/123456789/78486

Collections

Scopus 2021